关于 "Bromodomain" 的结果64+ 个结果
- GNE-781CAS: 1936422-33-1
GNE-781 (compound 19) is an orally active, highly potent and selective bromodomain inhibitor of cyclic adenosine monophosphate response element binding protein (CBP) with IC50 of 0.94 nM in TR-FRET assay. GNE-781 also inhibits BRET and BRD4(1) with IC50 of 6.2 nM and 5100 nM, respectively. GNE-781 exhibits antitumor activity.
- FL-411 (BRD4-IN-1)CAS: 2118944-88-8
FL-411 (BRD4-IN-1) is a potent and selective inhibitor of Bromodomain-containing protein 4 (BRD4) with IC50 of 0.43 μM for BRD4(1). FL-411 induces ATG5-dependent autophagy-associated cell death (ACD) by blocking BRD4-AMPK interaction.
- INCB054329CAS: 1628607-64-6
INCB054329 (INCB-054329, INCB-54329) is a structurally distinct bromodomain and extraterminal domain (BET) inhibitor with IC50 values of 44 nM, 5 nM, 9 nM, 1 nM, 28 nM, 3 nM, 119 nM and 63 nM for BRD2-BD1, BRD2-BD2, BRD3-BD1, BRD3-BD2, BRD4-BD1, BRD4-BD2, BRDT-BD1 and BRDT-BD2, respectively.
- Y06036CAS: 1832671-96-1
Y06036 (Compound 6i) is a potent and selective inhibitor of BET with antitumor activity. Y06036 binds to the BRD4(1) bromodomain with Kd of 82 nM.
- Thalidomide-NH-C4-NH-BocCAS: 2093388-52-2
Thalidomide-NH-C4-NH-Boc is a novel, potent, and selective class of Bromodomain-containing protein 4 (BRD4) and Bromodomain-containing protein 2 (BRD2) degrader for the development of therapeutics to treat cancers.
- BAZ1A-IN-1CAS: 941521-45-5
BAZ1A-IN-1 is a potent inhibitor of BAZ1A (bromodomain-containing protein), exerting a Kd value of 0.52 μM against BAZ1A bromodomain, shows good anti-viability activity against cancer cell lines expressing a high level of BAZ1A, but weak or no activity against cancer cells with a low expression level of BAZ1A.
- GNE-064CAS: 1997321-20-6
GNE-064 (compound 5) 是一种选择性的,具有口服活性的以及高可溶性的 SMARCA4,SMARCA2 和 PBRM1 bromodomains 5 抑制剂。GNE-064 对 SMARCA4 具有抑制作用,其 IC50 值为 0.035 μM,对 SMARCA2 也具有抑制作用,其 EC50 值为 0.10 μM。GNE-064 对 SMARCA4,SMARCA2,PBRM1 bromodomains 5 和 PBRM1 bromodomains 2 的 Kd 值为 0.01,0.016,0.018 以及 0.049 μM。GNE-064 可以作为一种药物探针,用于药物合成的研究。
- CD161CAS: 1627716-22-6
CD161 is a potent, orally active and selective BET bromodomain inhibitor (Ki values of 8.2 nM and 1.4 nM for BRD4 BD1 and BD2, respectively). CD161 inhibits cell growth in acute leukemia cell lines and breast cancer cell lines. Moreover, CD161 has an excellent oral pharmacokinetic profile and, orally administered, effectively inhibits tumor growth in mice.
- PLK1/BRD4-IN-2CAS: 2251709-89-2
PLK1/BRD4-IN-2(化合物15)是一种BI-2536类似物和双重抑制剂,靶向pol -like kinase 1 (PLK1)和BRD4bromodomain (BRD4-BD1 IC50=28 nM, PLK1 IC50=40 nM)。
| 货号 | 产品名称 | CAS号 | 靶点 / 通路 | 引用 | 结构 |
|---|---|---|---|---|---|
| GP22895 | BRD1 Human | - | Bromodomain Containing | ||
Bromodomain Containing 1 Human Recombinant | |||||
| GP22896 | BRD2 Human | - | Bromodomain Containing | ||
Bromodomain Containing 2 Human Recombinant | |||||
| GP22897 | BRD3 Human | - | Bromodomain Containing | ||
Bromodomain Containing 3 Human Recombinant | |||||
| GC31731 | GSK 4027 | 2079896-25-4 | Histone Acetyltransferases | ||
A PCAF/GCN5 bromodomain inhibitor | |||||
| GC32081 | GNE-781 | 1936422-33-1 | Histone Acetyltransferases | ||
GNE-781 (compound 19) is an orally active, highly potent and selective bromodomain inhibitor of cyclic adenosine monophosphate response element binding protein (CBP) with IC50 of 0.94 nM in TR-FRET assay. GNE-781 also inhibits BRET and BRD4(1) with IC50 of 6.2 nM and 5100 nM, respectively. GNE-781 exhibits antitumor activity. | |||||
| GC32812 | BMS-986158 | 1800340-40-2 | Epigenetic Reader Domain | ||
A BET bromodomain inhibitor | |||||
| GC33015 | FL-411 (BRD4-IN-1) | 2118944-88-8 | Epigenetic Reader Domain | ||
FL-411 (BRD4-IN-1) is a potent and selective inhibitor of Bromodomain-containing protein 4 (BRD4) with IC50 of 0.43 μM for BRD4(1). FL-411 induces ATG5-dependent autophagy-associated cell death (ACD) by blocking BRD4-AMPK interaction. | |||||
| GC33026 | INCB054329 | 1628607-64-6 | Epigenetic Reader Domain | ||
INCB054329 (INCB-054329, INCB-54329) is a structurally distinct bromodomain and extraterminal domain (BET) inhibitor with IC50 values of 44 nM, 5 nM, 9 nM, 1 nM, 28 nM, 3 nM, 119 nM and 63 nM for BRD2-BD1, BRD2-BD2, BRD3-BD1, BRD3-BD2, BRD4-BD1, BRD4-BD2, BRDT-BD1 and BRDT-BD2, respectively. | |||||
| GC33285 | Y06036 | 1832671-96-1 | Epigenetic Reader Domain | ||
Y06036 (Compound 6i) is a potent and selective inhibitor of BET with antitumor activity. Y06036 binds to the BRD4(1) bromodomain with Kd of 82 nM. | |||||
| GC62654 | GSK778 | 2451862-42-1 | Apoptosis | ||
GSK778 (iBET-BD1) is a strong BD1 bromodomain inhibitor of the BET proteins, with IC50 value of 75 nM for BRD2 BD1, 41 nM for BRD3 BD1, 41 nM for BRD4 BD1, and 143 nM for BRDT BD1. | |||||
| GC62722 | Thalidomide-NH-C4-NH-Boc | 2093388-52-2 | E3 Ligase Ligand-Linker Conjugate | ||
Thalidomide-NH-C4-NH-Boc is a novel, potent, and selective class of Bromodomain-containing protein 4 (BRD4) and Bromodomain-containing protein 2 (BRD2) degrader for the development of therapeutics to treat cancers. | |||||
| GC63694 | BAZ1A-IN-1 | 941521-45-5 | Epigenetic Reader Domain | ||
BAZ1A-IN-1 is a potent inhibitor of BAZ1A (bromodomain-containing protein), exerting a Kd value of 0.52 μM against BAZ1A bromodomain, shows good anti-viability activity against cancer cell lines expressing a high level of BAZ1A, but weak or no activity against cancer cells with a low expression level of BAZ1A. | |||||
| GC68439 | GNE-064 | 1997321-20-6 | Epigenetic Reader Domain | ||
GNE-064 (compound 5) 是一种选择性的,具有口服活性的以及高可溶性的 SMARCA4,SMARCA2 和 PBRM1 bromodomains 5 抑制剂。GNE-064 对 SMARCA4 具有抑制作用,其 IC50 值为 0.035 μM,对 SMARCA2 也具有抑制作用,其 EC50 值为 0.10 μM。GNE-064 对 SMARCA4,SMARCA2,PBRM1 bromodomains 5 和 PBRM1 bromodomains 2 的 Kd 值为 0.01,0.016,0.018 以及 0.049 μM。GNE-064 可以作为一种药物探针,用于药物合成的研究。 | |||||
| GC25183 | BZ1 | 2766623-38-3 | Others | ||
BZ1 (BPTF inhibitor, BPTF-IN-BZ1) is a pyridazinone-based BPTF (Bromodomain PHD Finger Transcription Factor) inhibitor with a high potency (Kd = 6.3 nM) and >350-fold selectivity over BET bromodomains. | |||||
| GB40142 | CD161 | 1627716-22-6 | - | ||
CD161 is a potent, orally active and selective BET bromodomain inhibitor (Ki values of 8.2 nM and 1.4 nM for BRD4 BD1 and BD2, respectively). CD161 inhibits cell growth in acute leukemia cell lines and breast cancer cell lines. Moreover, CD161 has an excellent oral pharmacokinetic profile and, orally administered, effectively inhibits tumor growth in mice. | |||||
| GC73884 | PLK1/BRD4-IN-2 | 2251709-89-2 | Epigenetic Reader Domain | ||
PLK1/BRD4-IN-2(化合物15)是一种BI-2536类似物和双重抑制剂,靶向pol -like kinase 1 (PLK1)和BRD4bromodomain (BRD4-BD1 IC50=28 nM, PLK1 IC50=40 nM)。 | |||||
